1-2 of 2
Ine Moors
Close
Sort by
Journal Articles

Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial

Clinical Trials & Observations
Gail J. Roboz, Guillermo Sanz, Elizabeth A. Griffiths, Karen Yee, Hagop Kantarjian, Christian Récher, Michael T. Byrne, Elżbieta Patkowska, Hee-Je Kim, Xavier Thomas, Ine Moors, Wendy Stock, Árpád Illés, Pierre Fenaux, Yasushi Miyazaki, Takahiro Yamauchi, Casey L. O'Connell, Yong Hao, Harold N. Keer, Mohammad Azab, Hartmut Döhner
Journal: Blood Advances
Blood Adv (2024) 8 (8): 2020–2029.
https://doi.org/10.1182/bloodadvances.2023012062
Published: 2024
Includes: Supplemental data
Journal Articles

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Clinical Trials & Observations
Bob Löwenberg, Thomas Pabst, Johan Maertens, Patrycja Gradowska, Bart J. Biemond, Olivier Spertini, Edo Vellenga, Laimonas Griskevicius, Lidwine W. Tick, Mojca Jongen-Lavrencic, Marinus van Marwijk Kooy, Marie-Christiane Vekemans, Walter J. F. M. van der Velden, Berna Beverloo, Lucienne Michaux, Carlos Graux, Dries Deeren, Okke de Weerdt, Joost W. J. van Esser, Mario Bargetzi, Saskia K. Klein, Alain Gadisseur, Peter E. Westerweel, Hendrik Veelken, Michael Gregor, Tobias Silzle, Daniëlle van Lammeren-Venema, Ine Moors, Dimitri A. Breems, Mels Hoogendoorn, Marie-Cecile J. C. Legdeur, Thomas Fischer, Juergen Kuball, Jan Cornelissen, Kimmo Porkka, Gunnar Juliusson, Peter Meyer, Martin Höglund, Bjorn T. Gjertsen, Jeroen J. W. M. Janssen, Gerwin Huls, Jakob Passweg, Jacqueline Cloos, Peter J. M. Valk, Catharina H. M. J. van Elssen, Markus G. Manz, Yngvar Floisand, Gert J. Ossenkoppele
Journal: Blood Advances
Blood Adv (2021) 5 (4): 1110–1121.
https://doi.org/10.1182/bloodadvances.2020003855
Published: 2021
Includes: Supplemental data